natgillin/translations-raw huggingface dataset:
In reproduction toxicity studies, decreased foetal weights in rats and rabbits (with associated delays in ossification) and foetal loss in rabbits have been observed with tigecycline. 
V študijah škodljivih vplivov na razmnoževanje so pri tigeciklinu opazili zmanjšano težo plodov pri podganah in kuncih (z njo je bila povezana tudi zapoznela kostenitev) in izgubo plodov pri kuncih.
Adolescents aged 12 to <18 years: 50 mg of tigecycline every 12 hours for 5 to 14 days. 
Mladostniki, stari od 12 do < 18 let: 50 mg tigeciklina vsakih 12 ur, 5 do 14 dni.
The effect of cholestasis in the pharmacokinetics of tigecycline has not been properly established. 
Vpliva holestaze na farmakokinetiko tigeciklina še niso temeljito raziskali.
Tigecycline is not extensively metabolised. 
Tigeciklin se ne presnavlja v večji meri.
• Injection site reaction (pain, redness, inflammation) 
• reakcija na mestu injiciranja (bolečina, rdečina, vnetje)
Pseudomembranous colitis may occur with most antibiotics including Tygacil. 
Psevdomembranski kolitis se lahko pojavi pri uporabi večine antibiotikov in tudi pri uporabi zdravila Tygacil.
The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. 
Informacije z lokalnega območja o odpornosti mikroorganizmov so zaželene, posebno še pri zdravljenju težkih okužb.
General disorders and administration site conditions impaired healing, injection site reaction, headache injection site inflammation, injection site pain, injection site oedema, injection site phlebitis 
Splošne težave in spremembe na mestu aplikacije slabše celjenje, reakcija na mestu injiciranja, glavobol vnetje na mestu injiciranja, bolečina na mestu injiciranja, edem na mestu injiciranja, flebitis na mestu injiciranja
Such reactions may include photosensitivity, pseudotumor cerebri, pancreatitis, and anti-anabolic action which has led to increased BUN, azotaemia, acidosis, and hyperphosphataemia (see section 4.8). 
Ti učinki lahko vključujejo preobčutljivost za svetlobo, benigno intrakranialno hipertenzijo, pankreatitis in antianabolno delovanje, ki lahko povzroči zvišan dušik sečnine v krvi, azotemijo, acidozo in hiperfosfatemijo (glejte poglavje 4.8).
Once reconstituted and diluted in the bag or other suitable infusion container (e.g. glass bottle) tigecycline should be used immediately. 
Ko je tigeciklin rekonstituiran in razredčen v vrečki ali drugem primernem vsebniku za infundiranje (na primer steklenici), ga morate uporabiti takoj.
Parenteral products should be inspected visually for particulate matter and discolouration (e.g., green or black) prior to administration. 
Zdravila za parenteralno uporabo morate s prostim očesom pregledati, da se prepričate, da ne vsebujejo delcev in da niso obarvana (na primer zeleno ali črno), preden jih vbrizgate bolniku.
Very common side effects are (may affect more than 1 in 10 people): 
Pogosti neželeni učinki so (pojavijo se lahko pri največ 1 od 10 bolnikov):
Consistent with the limited oral bioavailability of tigecycline, there is little or no systemic exposure to tigecycline in the nursing pups as a result of exposure via maternal milk. 
Dojeni mladiči so bili zaradi izpostavljenosti preko materinega mleka komaj kaj ali sploh nič sistemsko izpostavljeni tigeciklinu, kar se sklada z omejeno peroralno biološko uporabnostjo tigeciklina.
The recommended dose in adolescents aged 12 to <18 years is 50 mg given every 12 hours. 
Priporočeni odmerek pri mladostnikih, starih od 12 do < 18 let, je 50 mg vsakih 12 ur.
Tigecycline was not teratogenic in the rat or rabbit. 
Tigeciklin pri podganah in kuncih ni bil teratogen.
The powder should be reconstituted with 5.3 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, or Lactated Ringer's solution for injection to achieve a concentration of 10 mg/ml of tigecycline. 
Prašek morate rekonstituirati s 5,3 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje, 5-odstotne (50 mg/ml) raztopine glukoze za injiciranje ali z raztopino Ringerjevega laktata za injiciranje, tako da dosežete koncentracijo tigeciklina 10 mg/ml.
C-tigecycline indicates that 59 % of the dose is eliminated by biliary/faecal excretion, and 33 % is excreted in urine. 
Prestrežena celotna radioaktivnost v blatu in urinu po danem odmerku 14C-tigeciklina kaže, da se 59 % odmerka izloči iz telesa z žolčem in blatom, 33 % pa se ga izloči z urinom.
Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening. 
Pri skoraj vseh protibakterijskih zdravilih so poročali o psevdomembranskem kolitisu, katerega stopnja izraženosti lahko sega od blage do smrtno nevarne.
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients. 
Zaželeno je, da se tigeciklin pri pediatričnih bolnikih daje z infuzijo, ki traja 60 minut.
Acute pancreatitis, which can be serious, has occurred (frequency: uncommon) in association with tigecycline treatment (see section 4.8). 
V povezavi z zdravljenjem s tigeciklinom se pojavlja (pogostnost: občasno) akutni pankreatitis, ki je lahko resen (glejte poglavje 4.8).
Patients usually improve after tigecycline discontinuation. 
Po ukinitvi tigeciklina se stanje bolnikov navadno izboljša.
As a consequence, care should be paid to the rate of infusion of tigecycline in children and adolescents. 
Zaradi tega je pri otrocih in mladostnikih potrebna previdnosti pri hitrosti infundiranja tigeciklina.
Tygacil may cause foetal harm. 
Zdravilo Tygacil lahko škoduje plodu.
The first study enrolled children aged 8-16 years (n=24) who received single doses of tigecycline (0.5, 1, or 2 mg/kg, up to a maximum dose of 50 mg, 100 mg, and 150 mg, respectively) administered intravenously over 30 minutes. 
V prvo študijo so bili vključeni otroci, stari 8-16 let (n = 24), ki so prejeli enkratni odmerek tigeciklina (0,5, 1 ali 2 mg/kg, do največjega odmerka 50 mg, 100 mg oz. 150 mg), apliciran intravensko v času 30 minut.
However, systemic clearance of tigecycline was reduced by 25 % and 55 % and the half-life of tigecycline was prolonged by 23 % and 43 % in patients with moderate or severe hepatic impairment (Child Pugh B and C), respectively (see section 4.2). 
Pri bolnikih z zmerno oziroma s hudo okvaro jeter (razred B oziroma C po Child-Pughovi lestvici) pa se je sistemski očistek tigeciklina zmanjšal za 25 % oziroma 55 %, razpolovni čas tigeciklina pa podaljšal za 23 % oziroma 43 % (glejte poglavje 4.2).
Bolus intravenous administration of tigecycline has been associated with a histamine response in animal studies. 
V študijah na živalih je bilo intravensko dajanje tigeciklina v bolusu povezano s histaminskim odzivom.
The recommended dose for adults is an initial dose of 100 mg followed by 50 mg every 12 hours for 5 to 14 days. 
Priporočeni začetni odmerek za odrasle je 100 mg, ki mu sledi odmerek po 50 mg vsakih 12 ur, 5 do 14 dni.
Tetracycline class antibiotics 
Antibiotiki tetraciklinske skupine
Clearance, weight-normalised clearance, and AUC were not appreciably different among patients with different body weights, including those weighing ≥125 kg. AUC was 24 % lower in patients weighing ≥125 kg. No data is available for patients weighing 140 kg and more. 
Očistek, na telesno maso normalizirani očistek in AUC, se med bolniki z različno telesno maso, tudi pri tistih, ki so tehtali ≥ 125 kg, niso znatno razlikovali.
Once the powder has been made into a solution and diluted ready for use, it should be given to you immediately. 
Po pripravi raztopine in redčenju je zdravilo pripravljeno za uporabo; zdravilo morate prejeti takoj.
The recommended dose in children aged 8 to <12 years is 1.2 mg/kg given every 12 hours intravenously to a maximum dose of 50 mg every 12 hours. 
Priporočeni odmerek pri otrocih, starih od 8 do < 12 let, je 1,2 mg/kg vsakih 12 ur intravensko do največjega odmerka 50 mg vsakih 12 ur.
There is no target-based cross-resistance between tigecycline and most classes of antibiotics. 
Med tigeciklinom in večino skupin antibiotikov ni navzkrižne odpornosti na podlagi tarče.
Hepatobiliary disorders elevated aspartate aminotransferase (AST) in serum, and elevated alanine aminotransferase (ALT) in serum, hyperbilirubinaemia jaundice, liver injury, mostly cholestatic hepatic failure 
Bolezni jeter, žolčnika in žolčevodov zvišanje aspartataminotransferaze (AST) v serumu in zvišanje alaninaminotransferaze (ALT) v serumu, hiperbilirubinemija zlatenica, poškodba jeter, večinoma holestatska odpoved jeter (glejte poglavje 4.4)
Vascular disorders phlebitis thrombophlebitis 
Žilne bolezni flebitis tromboflebitis
What Tygacil looks like and contents of the pack Tygacil is supplied as a powder for solution for infusion in a vial and looks like an orange powder or cake before it is diluted. 
Pred redčenjem je videti kot oranžen prašek ali pogača.
• Increase in amylase, which is an enzyme found in the salivary glands and pancreas, increased blood urea nitrogen (BUN). 
• zvišana raven amilaze, encima, ki ga najdemo v žlezah slinavkah in trebušni slinavki, zvišana raven dušika sečnine v krvi (BUN)
Results from animal studies using 
Rezultati študij na živalih, pri katerih so uporabljali tigeciklin, označen s
Anaphylaxis/anaphylactoid reactions, potentially life-threatening, have been reported with tigecycline (see sections 4.3 and 4.8). 
Pri tigeciklinu so poročali o anafilaksiji/anafilaktoidnih reakcijah, ki so lahko smrtno nevarne (glejte poglavji 4.3 in 4.8).
Children aged 8 to <12 years: 1.2 mg/kg of tigecycline every 12 hours intravenously to a maximum dose of 50 mg every 12 hours for 5 to 14 days. 
Otroci, stari od 8 do < 12 let: 1,2 mg/kg tigeciklina vsakih 12 ur intravensko do največjega odmerka 50 mg vsakih 12 ur, 5 do 14 dni.
The second study was performed in children aged 8 to 11 years who received multiple doses of tigecycline (0.75, 1, or 1.25 mg/kg up to a maximum dose of 50 mg) every 12 hours administered intravenously over 30 minutes. 
V drugo študijo so bili vključeni otroci, stari 8-11 let, ki so prejeli večkratne odmerke tigeciklina (0,75, 1 ali 1,25 mg/kg, do največjega odmerka 50 mg) vsakih 12 ur, aplicirane intravensko v času 30 minut.
• Abdominal pain, dyspepsia (stomach ache and indigestion), anorexia (loss of appetite) 
• bolečine v trebuhu, dispepsija (bolečine v trebuhu in prebavne težave), anoreksija
No dosage adjustment is necessary in patients with renal impairment or in patients undergoing haemodialysis (see section 5.2). 
Pri bolnikih z okvaro ledvic in pri bolnikih, ki se zdravijo s hemodializo, prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
The recommended dose in adults is 100 mg given initially, followed by 50 mg every 12 hours. 
Priporočeni začetni odmerek pri odraslih je 100 mg, nato pa 50 mg vsakih 12 ur.
The single dose pharmacokinetic disposition of tigecycline was not altered in patients with renal insufficiency (creatinine clearance 30 ml/min, n=6). 
Pri bolnikih z insuficienco ledvic (očistek kreatinina < 30 ml/min, n = 6) se farmakokinetika tigeciklina po enkratnem odmerku ni spremenila.
Nervous system disorders dizziness 
Bolezni živčevja omotica
In repeated dose toxicity studies in rats and dogs, lymphoid depletion/atrophy of lymph nodes, spleen and thymus, decreased erythrocytes, reticulocytes, leukocytes, and platelets, in association with bone marrow hypocellularity, and adverse renal and gastrointestinal effects have been seen with tigecycline at exposures of 8 and 10 times the human daily dose based on AUC in rats and dogs, respectively. 
V raziskavah toksičnosti ponavljajočih se odmerkov na podganah in psih so pri tigeciklinu ob izpostavljenosti, ki je bila 8-krat oziroma 10-krat večja od dnevnega odmerka za ljudi na podlagi AUC pri podganah oziroma psih, ugotovili limfoidno osiromašenje/atrofijo bezgavk, vranice in priželjca, zmanjšane koncentracije eritrocitov, retikulocitov, levkocitov in trombocitov v povezavi z zmanjšanim številom celic v kostnem mozgu in škodljive učinke na ledvicah in prebavilih.
Compatible intravenous solutions include: sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, and Lactated Ringer's solution for injection. 
Med kompatibilnimi intravenskimi raztopinami so 0,9-odstotna (9 mg/ml) raztopina natrijevega klorida za injiciranje, 5-odstotna (50 mg/ml) raztopina glukoze za injiciranje in raztopina Ringerjevega laktata za injiciranje.
Each vial contains 50 mg tigecycline. 
Ena viala vsebuje 50 mg tigeciklina.
Thereafter, 5 ml of the reconstituted solution should be immediately withdrawn from the vial and added to a 100 ml intravenous bag for infusion or other suitable infusion container (e.g. glass bottle). 
Takoj nato odvzemite 5 ml rekonstituirane raztopine iz viale in jo dodajte v 100-mililitrsko vrečko za intravensko infuzijo ali drug primeren vsebnik za infuzijo (na primer steklenico).
• Acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting) 
• akutni pankreatitis (vnetje trebušne slinavke, ki lahko povzroči hude bolečine v trebuhu, slabost s siljenjem na bruhanje (navzea) in bruhanje)
For a 100 mg dose, reconstitute using two vials into a 100 ml intravenous bag for infusion or other suitable infusion container (e.g. glass bottle). 
Za 100-miligramski odmerek rekonstituirajte dve viali v 100-mililitrsko vrečko za intravensko infuzijo ali drug primeren vsebnik za infuzijo (na primer steklenico).
Tygacil 50 mg powder for solution for infusion 
Tygacil 50 mg prašek za raztopino za infundiranje
other than S. pneumoniae S  0.25 mg/L and R  0.5 mg/L Enterococcus spp. 
S  0,5 mg/l in R > 0,5 mg/l Streptococcus spp., razen S. pneumoniae, S  0,25 mg/l in R > 0,5 mg/l Enterococcus spp.
Gram-negative Aerobes 
Gramnegativni aerobi
No significant effect of a single intravenous dose of tigecycline 50 mg or 200 mg on QTc interval was detected in a randomized, placebo- and active-controlled four-arm crossover thorough QTc study of 46 healthy subjects. 
V randomizirani, s placebom in učinkovino nadzorovani navzkrižni podrobni študiji QTc s štirimi skupinami, pri 46 zdravih preiskovancih niso ugotovili pomembnega učinka enkratnega intravenskega odmerka 50 mg ali 200 mg tigeciklina na interval QTc.
Prothrombin time or other suitable anticoagulation test should be used to monitor patients if tigecycline is administered with anticoagulants (see section 4.5). 
Bolnike, ki jim dajemo tigeciklin skupaj z antikoagulanti, moramo spremljati s testiranjem protrombinskega časa ali kakim drugim primernim koagulacijskim testom (glejte poglavje 4.5).
Investigations elevated amylase in serum, increased blood urea nitrogen (BUN) 
Preiskave zvišana amilaza v serumu, zvišan dušik sečnine v krvi (BUN) neželeni učinki, ugotovljeni v obdobju trženja
Multiple dose 
enkratni odmerek večkratni odmerki
Tetracycline class adverse reactions may include photosensitivity, pseudotumour cerebri, pancreatitis, and antianabolic action which has led to increased BUN, azotaemia, acidosis, and hyperphosphataemia (see section 4.4). 
Med neželenimi učinki zdravil iz skupine tetraciklinov so lahko preobčutljivost za svetlobo, benigna intrakranialna hipertenzija, pankreatitis in antianabolno delovanje, ki lahko povzroči zvišan dušik sečnine v krvi, azotemijo, acidozo in hiperfosfatemijo (glejte poglavje 4.4).
Adult dose should be reduced to 25 mg every 12 hours following the 100 mg loading dose. 
Odmerek za odrasle je treba, po polnilnem odmerku 100 mg, zmanjšati na 25 mg vsakih 12 ur.
Tigecycline in recommended dosage did not affect the rate or extent of absorption, or clearance of digoxin (0.5 mg followed by 0.25 mg daily) when administered in healthy adults. 
Ko so tigeciklin v priporočenih odmerkih (0,5 mg, nato 0,25 mg na dan) dajali zdravim odraslim, ni vplival na hitrost ali obseg absorpcije, niti na očistek digoksina.
Tygacil 50 mg powder for infusion Tigecycline 
Tygacil 50 mg prašek za raztopino za infundiranje tigeciklin
Tygacil may cause side effects such as dizziness. 
Zdravilo Tygacil lahko povzroči neželene učinke, kot na primer omotico.
• Anaphylaxis/anaphylactoid reactions (that may range from mild to severe, including a sudden, 
• anafilaksija/anafilaktoidne reakcije (ki so lahko blage do težke, vključno z nenadno generalizirano alergijsko reakcijo, ki lahko povzroči smrtno nevaren šok [npr. oteženo dihanje,
Each 5 ml Tygacil vial contains 50 mg of tigecycline. 
Ena 5-mililitrska viala zdravila Tygacil vsebuje 50 mg tigeciklina.
Viridans group streptococci 
Streptokoki skupine viridans
Consideration should be given to the use of combination antibacterial therapy whenever tigecycline is to be administered to severely ill patients with cIAI secondary to clinically apparent intestinal perforation or patients with incipient sepsis or septic shock (see section 4.8). 
Kadarkoli nameravamo dati tigeciklin hudo bolnim bolnikom s cIAI, ki so nastale zaradi klinično očitne perforacije črevesa, ali bolnikom z začetno sepso ali septičnim šokom, moramo pretehtati možnost kombiniranega protibakterijskega zdravljenja (glejte poglavje 4.8).
Liver function tests, coagulation parameters, haematology parameters, amylase and lipase should be monitored prior to treatment initiation with tigecycline and regularly while on treatment. 
Pred uvedbo zdravljenja s tigeciklinom in redno med zdravljenjem je treba spremljati izvide testov jetrne funkcije, koagulacijske parametre, hematološke parametre, amilazo in lipazo.
• Pruritus (itching), rash 
• pruritus (srbenje), kožni izpuščaj
Race There were no differences in the clearance of tigecycline based on race. 
Rasa Očistek tigeciklina se med pripadniki različnih ras ni razlikoval.
Talk to your doctor or nurse before receiving Tygacil: 
Pred začetkom prejemanja zdravila Tygacil se posvetujte z zdravnikom ali medicinsko sestro:
No evidence of photosensitivity was observed in rats following administration of tigecycline. 
Po uporabi tigeciklina niso pri podganah opazili nikakršnih dokazov preobčutljivosti za svetlobo.
The vial should be gently swirled until the active substance is dissolved. 
Vialo nežno vrtite, dokler se zdravilna učinkovina ne raztopi.
C-tigecycline, unchanged tigecycline was the primary 
C-tigeciklin, primarna snov, označena s
If the same intravenous line is used for sequential infusion of several active substances, the line should be flushed before and after infusion of tigecycline with either sodium chloride 9 mg/ml (0.9 %) solution for injection or dextrose 50 mg/ml (5 %) solution for injection. 
Tigeciklin morate aplicirati intravensko po ločenem infuzijskem kanalu ali skozi podaljšek Y. Če uporabljate intravenski kanal za zaporedno infundiranje več različnih učinkovin, ga morate pred infuzijo tigeciklina in po njej splakniti bodisi z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje bodisi s 5-odstotno (50 mg/ml) raztopino glukoze za injiciranje.
The single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment. 
Pri bolnikih z blago okvaro jeter se farmakokinetika tigeciklina po enkratnem odmerku ni spremenila.
• Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4); 
• zapletene okužbe kože in mehkih tkiv (complicated skin and soft tissue infections - cSSTI),
Tygacil is distributed in a ten vial tray pack. 
Zdravilo Tygacil je na voljo v škatli s podstavkom z desetimi vialami.
Tygacil may interfere with the contraceptive pill (birth control pill). 
Zdravilo Tygacil lahko zmanjša delovanje kontracepcijskih tablet.
Ask your doctor for advice before breast-feeding your baby. 
Preden začnete dojiti svojega otroka, se posvetujte z zdravnikom.
Lactose monohydrate Hydrochloric acid 
6.1 Seznam pomožnih snovi laktoza monohidrat klorovodikova kislina natrijev hidroksid (za uravnavanje pH)
generalised allergic reaction that may lead to a life-threatening shock [e.g. difficulty in breathing, drop of blood pressure, fast pulse]). 
padec krvnega tlaka, pospešen srčni utrip])
Tetracycline class effects 
Učinki zdravil iz skupine tetraciklinov
What Tygacil contains The active substance is tigecycline. 
Zdravilna učinkovina je tigeciklin.
Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis. 
Kadar posumimo, da se razvija pankreatitis, moramo razmisliti o prekinitvi zdravljenja s tigeciklinom.
As the Patient Alert Card is part of the product information in the outer packaging, the content will be centrally approved for all EU/EEA languages without need of further approval by National Authorities. 
Ker je opozorilna kartica za bolnika del povzetka glavnih značilnosti zdravila v zunanjem pakiranju, bo vsebina centralno odobrena za vse jezike EU/EGS, pri čemer dodatna odobritev s strani nacionalnih organov ni potrebna.
• Periodic safety update reports (PSUR) 
• Redno posodobljena poročila o varnosti zdravila (PSUR)
A Patient Alert Card will be included in the carton. 
Opozorilna kartica za bolnika bo priložena v škatli.
Do not have Riximyo if you have an active infection or a serious problem with your immune system. 
Zdravila Riximyo ne smete prejeti, če imate aktivno okužbo ali resno težavo s svojim imunskim sistemom.
Patients should receive Riximyo for at least 24 months after achievement of remission (absence of clinical signs and symptoms). 
Riximyo prejemati vsaj 24 mesecev po doseženi remisiji (odsotnost kliničnih znakov in simptomov).
• Show this card to any doctor, nurse or dentist you see - not just the specialist who prescribes your Riximyo. 
• Pokažite jo vsem zdravnikom, medicinskim sestram in zobozdravnikom, ki jih obiščete - ne samo specialistu, ki vam predpiše zdravilo Riximyo.
Your doctor may decide to treat you longer with Riximyo (up to 5 years), depending on how you respond to the medicine. 
Zdravnik se lahko odloči, da vas bo z zdravilom Riximyo zdravil dlje (do 5 let), odvisno od tega, kako se odzovete na zdravilo.
Riximyo may also cause changes in laboratory tests carried out by your doctor. 
Zdravilo Riximyo lahko vpliva tudi na spremembe laboratorijskih preiskav, ki jih naroči vaš zdravnik.
Your doctor may decide to stop your Riximyo treatment if these reactions are serious. 
Zdravnik se lahko odloči za prenehanje zdravljenja z zdravilom Riximyo, če so te reakcije resne.
Currently, there are limited data on possible interactions with other medicinal products and rituximab. 
Trenutno je le malo podatkov o mogočih medsebojnih učinkih drugih zdravil in rituksimaba.
Riximyo will be given to you by a doctor or nurse who is experienced in the use of this treatment. 
Zdravilo Riximyo vam bo dal zdravnik ali medicinska sestra, ki ima izkušnje z uporabo takšnih zdravil.
Efficacy was observed both for patients with newly diagnosed disease and for patients with relapsing disease (Table 13). 
Učinkovitost so ugotovili tako pri bolnikih z novoodkrito boleznijo kot pri bolnikih s ponovitvijo bolezni (preglednica 13).
If you can get pregnant, you and your partner must use an effective method of contraception while using Riximyo. 
Če bi lahko zanosili, morate vi in vaš partner med uporabo zdravila Riximyo uporabljati učinkovito kontracepcijsko zaščito.
Before you are given Riximyo you will be given other medicines (premedication) to prevent or reduce possible side effects. 
Preden boste dobili zdravilo Riximyo, boste dobili druga zdravila (to imenujemo premedikacija) za preprečitev ali zmanjšanje možnih neželenih učinkov.
Riximyo in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes. 
Zdravilo Riximyo v kombinaciji s kemoterapijo uniči te celice, ki se postopno odstranijo iz telesa z biološkimi procesi.
Patients reporting signs and symptoms of infection following Riximyo therapy should be promptly evaluated and treated appropriately. 
Bolnike, pri katerih se pojavijo znaki in simptomi okužbe po zdravljenju z zdravilom Riximyo, je treba nemudoma pregledati in primerno zdraviti.
Riximyo is indicated in adults for the following indications: 
Zdravilo Riximyo je pri odraslih indicirano za naslednje indikacije: